Incyte Genomics Inc vs Eli Lilly & Co.
INCY vs LLY — side-by-side comparison from reported financials. INCY leads 2, LLY leads 7 of 9 comparable metrics.
Incyte Genomics Inc
INCY · Healthcare
$112.79+0.04%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | INCY | LLY |
|---|---|---|
| Price | $112.79 | $1 177.20 |
| Market cap | $22.9B | $1.05T |
| Revenue (TTM) | $5.82B | $79.7B |
| Revenue growth | +14.8% | +31.7% |
| Net margin | 27.7% | 33.5% |
| Free cash flow | $1.98B | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +33.1% | +37.6% |
| P/E | 14.2 | 41.6 |
| P/E vs own history (cheap-side %) | 96% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 30% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 9 of 10 | 11 of 10 |
| Employees | 2,844 | 50,000 |
Full résumé-style profiles: INCY CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.